Skip to main content
Fig. 5 | Translational Neurodegeneration

Fig. 5

From: Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model

Fig. 5

Hyperglycemia increases α-syn aggregation and phosphorylation in the nigrostriatal system in α-syn-overexpressing mice. (a) Western blot analyses of α-syn and phosphorylated α-syn (pS129) levels in mouse SN. (b, c) Quantification of α-syn and pS129-α-syn protein levels (n = 3 to 4 mice/group). (d) Western blot analyses of Triton-soluble α-syn (Trx soluble) and Triton-insoluble α-syn (Trx insoluble) in mouse SN. (ef) Quantification of relative expression of Trx-soluble and Trx-insoluble α-syn by intensity measurement (n = 3 per group). (g) Representative immunohistochemical images of pS129-α-syn in the SN of WT and BAC-α-syn-GFP mice at one and three months after injections. Images in the right column are higher magnifications of boxed areas in the left column. (h) Representative images of two different types of pS129-α-syn-positive nigral neurons. h1 and h2 show neurons containing pS129-positive inclusions, while h3 shows a neuron with diffused staining. h4 shows the pS129 staining in SN reticulata, where significant positive profile is present in BAC mice (right panel). (i, j) Stereological quantification of pS129-α-syn-positive nigral neurons in the SNpc (i) and the proportion of remaining nigral neurons containing α-syn inclusions (j). WT + vehicle (n = 4/4 mice at one/three months after injections, respectively); WT + STZ (n = 4/3 mice at one/three months after injections, respectively); α-syn + vehicle (n = 4/4 mice at one/three months after injections, respectively); α-syn + STZ (n = 4/4 mice at one/three months after injections, respectively). Scale bars: (g) left column, 200 µm; right column, 50 µm; (h) h1h3, 10 µm; h4, 50 µm. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page